BioCardia Earnings Call: Key Takeaways
BioCardia is pivoting toward Japanese regulatory approval for Cardiamp and US de novo approval for Helix, while managing a tight $2.2 million cash runway into 2027.
- Call
- Nov 12, 2026, 4:30 PM ET
ALFA USA Filings
Every alert, straight from SEC EDGAR
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BioCardia, Inc. filings on SEC EDGAR ↗
Filing type
Alerts
Time
9 alerts with these filters
BioCardia is pivoting toward Japanese regulatory approval for Cardiamp and US de novo approval for Helix, while managing a tight $2.2 million cash runway into 2027.
BioCardia reported financial results for the third quarter ended September 30, 2026, and provided updates on its regulatory progress in Japan and the U.S. The company successfully completed pre-submission interactions with Japan's PMDA for its CardiAMP cell therapy and expects to file for FDA De Novo approval of its Helix delivery system in Q1 2027.
“We believe that our CardiAMP autologous cell therapy is on track to be the first approved minimally invasive biologic therapy for the treatment of heart failure in a first world country based on the recent interactions with Japan’s Pharmaceutical and Medical Devices Agency.”
Peter Altman, PhD, Chief Executive Officer of BioCardia
“In addition, in the coming months, we aim to be able to submit our Helix transendocardial delivery platform for FDA approval, which would be the first delivery system of its type approved in the United States. This promises to be an exciting year ahead.”
Peter Altman, PhD, Chief Executive Officer of BioCardia
BioCardia, Inc. reported a net loss of $5.7 million for the nine months ended September 30, 2026, compared to a $6.2 million loss in the prior year period. The company ended the quarter with $2.2 million in cash and cash equivalents, supported by $5.3 million in proceeds from common stock sales during the year.
BioCardia has completed the clinical consultation process with Japan's PMDA regarding application materials for its CardiAMP Cell Therapy System. This milestone allows the company to advance toward a formal marketing approval application for the treatment of ischemic heart failure in Japan, with initial patient treatments and commercial revenues targeted for 2028.
BioCardia announced that the FDA has accepted its revised De Novo pre-submission package for the marketing clearance of its Helix transendocardial delivery catheter. The company expects a substantive review and a meeting with the FDA to discuss the approval pathway during the current quarter.
BioCardia announced it will present the trial design and scientific support for its CardiAMP HF II Study at the Heart Failure Society of America Annual Scientific Meeting. The study evaluates a high-dose autologous cell treatment for patients with ischemic heart failure of reduced ejection fraction (HFrEF) who remain symptomatic despite medical therapy.
BioCardia has submitted a revised Pre-Submission to the FDA Center for Devices and Radiological Health (CDRH) for the approval of its Helix Catheter for therapeutic and diagnostic delivery to the heart. The submission incorporates prior FDA feedback regarding marketing clearance pathways and safety data, with the FDA expected to provide written feedback or hold a meeting within 70 days. An independent clearance would allow BioCardia to partner with other developers of cell, gene, and protein therapeutics requiring targeted cardiac delivery.
BioCardia provided a regulatory and clinical update, confirming plans to submit a Shonin pre-market application to Japan's PMDA in Q4 2026 for its CardiAMP cell therapy. The company also intends to file a De Novo pre-submission with the FDA this quarter for its Helix Transendocardial Delivery Catheter System, which could expand its partnership opportunities for cardiac therapeutics.
BioCardia has regained compliance with Nasdaq's $1.00 minimum bid price requirement after its common stock closed at or above $1.00 per share for at least 10 consecutive business days. The company had previously received a deficiency notice on August 19, 2026, and Nasdaq has now officially closed the matter. The company's common stock will continue to trade on The Nasdaq Capital Market under the symbol 'BCDA'.